Generic Tessalon Availability
Tessalon is a brand name of benzonatate, approved by the FDA in the following formulation(s):
TESSALON (benzonatate - capsule;oral)
-
Manufacturer: PFIZER
Approved Prior to Jan 1, 1982
Strength(s): 100MG [AA] -
Manufacturer: PFIZER
Approval date: June 25, 1999
Strength(s): 200MG
Has a generic version of Tessalon been approved?
Yes. The following products are equivalent to Tessalon:
benzonatate capsule;oral
-
Manufacturer: APOTEX INC
Approval date: January 16, 2015
Strength(s): 100MG [AA] -
Manufacturer: BIONPHARMA INC
Approval date: January 29, 1993
Strength(s): 100MG [AA] -
Manufacturer: MIKART
Approval date: November 9, 2009
Strength(s): 100MG [AA] -
Manufacturer: ORIT LABS LLC
Approval date: July 30, 2007
Strength(s): 100MG [AA] -
Manufacturer: STRIDES PHARMA
Approval date: July 30, 2015
Strength(s): 100MG [AA] -
Manufacturer: SUN PHARM INDS INC
Approval date: March 19, 2008
Strength(s): 100MG [AA] -
Manufacturer: ZYDUS PHARMS USA
Approval date: June 8, 2007
Strength(s): 100MG [AA]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tessalon. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
More about Tessalon (benzonatate)
Consumer resources
- Other brands: Zonatuss
Professional resources
Other formulations
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| AA | Products in conventional dosage forms not presenting bioequivalence problems. Products coded as AA contain active ingredients and dosage forms that are not regarded as presenting either actual or potential bioequivalence problems or drug quality or standards issues. However, all oral dosage forms must, nonetheless, meet an appropriate in vitro bioequivalence standard that is acceptable to the Agency in order to be approved. |
